PCSK9 inhibitors induce a marked reduction in LDL cholesterol levels and subsequent cardiovascular events, especially beneficial for patients with familial hypercholesterolemia or statin intolerance [26]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.